Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas

Molecular Cancer

Volumn 7, Issue , 2008, Pages

  Field, Kenneth A ^a   Charoenthongtrakul, Soratree ^a   Michael, J Michael ^b   Refaeli, Yosef ^c,d  

^a BUCKNELL UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; LONAFARNIB; MYC PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; DRUG DERIVATIVE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; METHIONINE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GENE OVEREXPRESSION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; SURVIVAL TIME; TRANSGENIC MOUSE; TREATMENT DURATION; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; LYMPHOCYTE; METABOLISM; PATHOLOGY; REMISSION; TUMOR CELL LINE;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FLOW CYTOMETRY; LYMPHOCYTES; LYMPHOMA, B-CELL; METHIONINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PIPERIDINES; PYRIDINES; REMISSION INDUCTION;

EID: 44949153485     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-7-39     Document Type: Article

References (54)

1. Cox AD Der CJ Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1997, 1333(1):F51-71 9294018
2. Sepp-Lorenzino L Ma Z Rands E Kohl NE Gibbs JB Oliff A Rosen N A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines Cancer Res 1995, 55(22):5302-5309 7585592
3. Feldkamp MM Lau N Guha A Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects Oncogene 1999, 18(52):7514-7526 10.1038/sj.onc.1203105 10602510
4. van Golen KL Bao L DiVito MM Wu Z Prendergast GC Merajver SD Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor Mol Cancer Ther 2002, 1(8):575-583 12479217
5. Sirotnak FM Sepp-Lorenzino L Kohl NE Rosen N Scher HI A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility Cancer Chemother Pharmacol 2000, 46(1):79-83 10.1007/ s002800000126 10912583
6. Kohl NE Omer CA Conner MW Anthony NJ Davide JP deSolms SJ Giuliani EA Gomez RP Graham SL Hamilton K Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nat Med 1995, 1(8):792-797 10.1038/nm0895-792 7585182
7. Barrington RE Subler MA Rands E Omer CA Miller PJ Hundley JE Koester SK Troyer DA Bearss DJ Conner MW Gibbs JB Hamilton K Koblan KS Mosser SD O'Neill TJ Schaber MD Senderak ET Windle JJ Oliff A Kohl NE A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis Mol Cell Biol 1998, 18(1):85-92 121456 9418856
8. Mangues R Corral T Kohl NE Symmans WF Lu S Malumbres M Gibbs JB Oliff A Pellicer A Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice Cancer Res 1998, 58(6):1253-1259 9515813
9. Mahgoub N Taylor BR Gratiot M Kohl NE Gibbs JB Jacks T Shannon KM In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells Blood 1999, 94(7):2469-2476 10498620
10. Norgaard P Law B Joseph H Page DL Shyr Y Mays D Pietenpol JA Kohl NE Oliff A Coffey RJ Jr. Poulsen HS Moses HL Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis Clin Cancer Res 1999, 5(1):35-42 9918200
11. Omer CA Chen Z Diehl RE Conner MW Chen HY Trumbauer ME Gopal-Truter S Seeburger G Bhimnathwala H Abrams MT Davide JP Ellis MS Gibbs JB Greenberg I Koblan KS Kral AM Liu D Lobell RB Miller PJ Mosser SD O'Neill TJ Rands E Schaber MD Senderak ET Oliff A Kohl NE Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl: protein transferase inhibitor Cancer Res 2000, 60(10):2680-2688 10825141
12. Adjei AA Erlichman C Davis JN Cutler DL Sloan JA Marks RS Hanson LJ Svingen PA Atherton P Bishop WR Kirschmeier P Kaufmann SH A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity Cancer Res 2000, 60(7):1871-1877 10766174
13. Eskens FA Awada A Cutler DL de Jonge MJ Luyten GP Faber MN Statkevich P Sparreboom A Verweij J Hanauske AR Piccart M Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors J Clin Oncol 2001, 19(4):1167-1175 11181683
14. Khuri FR Glisson BS Kim ES Statkevich P Thall PF Meyers ML Herbst RS Munden RF Tendler C Zhu Y Bangert S Thompson E Lu C Wang XM Shin DM Kies MS Papadimitrakopoulou V Fossella FV Kirschmeier P Bishop WR Hong WK Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors Clin Cancer Res 2004, 10(9):2968-2976 10.1158/ 1078-0432.CCR-03-0412 15131032
15. Sharma S Kemeny N Kelsen DP Ilson D O'Reilly E Zaknoen S Baum C Statkevich P Hollywood E Zhu Y Saltz LB A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan Ann Oncol 2002, 13(7):1067-1071 10.1093/ annonc/mdf173 12176785
16. Glass TL Liu TJ Yung WK Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336 Neuro-oncol 2000, 2(3):151-158 1920495 11302335 10.1215/15228517-2-3-151
17. Peters DG Hoover RR Gerlach MJ Koh EY Zhang H Choe K Kirschmeier P Bishop WR Daley GQ Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia Blood 2001, 97(5):1404-1412 10.1182/blood.V97.5.1404 11222387
18. Ganguly AK Doll RJ Girijavallabhan VM Farnesyl protein transferase inhibition: A novel approach to anti-tumor therapy. The discovery and development of SCH 66336 Curr Med Chem 2001, 8(12):1419-1436 11562275
19. Liu M Bishop WR Nielsen LL Bryant MS Kirschmeier P Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models Methods Enzymol 2001, 333:306-318 11400347
20. Liu M Bryant MS Chen J Lee S Yaremko B Lipari P Malkowski M Ferrari E Nielsen L Prioli N Dell J Sinha D Syed J Korfmacher WA Nomeir AA Lin CC Wang L Taveras AG Doll RJ Njoroge FG Mallams AK Remiszewski S Catino JJ Girijavallabhan VM Bishop WR Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice Cancer Res 1998, 58(21):4947-4956 9810004
21. Reichert A Heisterkamp N Daley GQ Groffen J Treatment of Bcr/ Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336 Blood 2001, 97(5):1399-1403 10.1182/blood.V97.5.1399 11222386
22. Brunner TB Hahn SM Gupta AK Muschel RJ McKenna WG Bernhard EJ Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations Cancer Res 2003, 63(18):5656-5668 14522880
23. Harousseau JL Farnesyltransferase inihibitors in hematologic malignancies Blood Rev 2007, 21(4):173-182 10.1016/j.blre.2006.12.001 17293017
24. Goemans BF Zwaan CM Harlow A Loonen AH Gibson BE Hahlen K Reinhardt D Creutzig U Heinrich MC Kaspers GJ In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets Blood 2005, 106(10):3532-3537 10.1182/blood-2005-04-1640 16051737
25. Koh WS Yoon SY Kwon BM Jeong TC Nam KS Han MY Cinnamaldehyde inhibits lymphocyte proliferation and modulates T-cell differentiation Int J Immunopharmacol 1998, 20(11):643-660 10.1016/S0192-0561(98)00064-2 9848396
26. Si MS Ji P Tromberg BJ Lee M Kwok J Ng SC Imagawa DK Farnesyltransferase inhibition: A novel method of immunomodulation Int Immunopharmacol 2003, 3(4):475-483 10.1016/S1567-5769(02)00278-3 12689653
27. Si MS Reitz BA Borie DC Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123 Invest New Drugs 2005, 23(1):21-29 10.1023/B:DRUG.0000047102.26698.08 15528977
28. Greenwood J Steinman L Zamvil SS Statin therapy and autoimmune disease: from protein prenylation to immunomodulation Nat Rev Immunol 2006, 6(5):358-370 10.1038/nri1839 16639429
29. Refaeli Y Field KA Turner BC Trumpp A Bishop JM The protooncogene MYC can break B cell tolerance Proc Natl Acad Sci U S A 2005, 102(11):4097-4102 552974 15753301 10.1073/pnas.0409832102
30. Refaeli Y Young RM Turner BC Duda J Field KA Bishop JM The B-cell antigen receptor and overexpression of MYC can cooperate in the genesis of B-cell lymphomas PLoS Biology
31. Kovalchuk AL Qi CF Torrey TA Taddesse-Heath L Feigenbaum L Park SS Gerbitz A Klobeck G Hoertnagel K Polack A Bornkamm GW Janz S Morse HC 3rd Burkitt lymphoma in the mouse J Exp Med 2000, 192(8):1183-1190 2195876 11034608 10.1084/jem.192.8.1183
32. Park SS Kim JS Tessarollo L Owens JD Peng L Han SS Tae Chung S Torrey TA Cheung WC Polakiewicz RD McNeil N Ried T Mushinski JF Morse HC 3rd Janz S Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice Cancer Res 2005, 65(4):1306-1315 10.1158/0008-5472.CAN-04-0268 15735016
33. Zhu D Qi CF Morse HC 3rd Janz S Stevenson FK Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells Blood 2005, 105(5):2135-2137 10.1182/blood-2004-07-2573 15522957
34. Wang J Boxer LM Regulatory elements in the immunoglobulin heavy chain gene 3′-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells J Biol Chem 2005, 280(13):12766-12773 10.1074/ jbc.M412446200 15687498
35. Kuppers R Mechanisms of B-cell lymphoma pathogenesis Nat Rev Cancer 2005, 5(4):251-262 10.1038/nrc1589 15803153
36. Evens AM Gordon LI Burkitt's and Burkitt-like lymphoma Curr Treat Options Oncol 2002, 3(4):291-305 10.1007/s11864-002-0029-9 12074766
37. Cairo MS Bishop M Tumour lysis syndrome: New therapeutic strategies and classification Br J Haematol 2004, 127(1):3-11 10.1111/ j.1365-2141.2004.05094.x 15384972
38. Goodnow CC Crosbie J Adelstein S Lavoie TB Smith-Gill SJ Brink RA Pritchard-Briscoe H Wotherspoon JS Loblay RH Raphael K Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice Nature 1988, 334(6184):676-682 10.1038/ 334676a0 3261841
39. Haluska P Dy GK Adjei AA Farnesyl transferase inhibitors as anticancer agents Eur J Cancer 2002, 38(13):1685-1700 10.1016/S0959-8049(02)00166-1 12175684
40. Lebowitz PF Prendergast GC Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho Oncogene 1998, 17(11 Reviews):1439-1445 10.1038/ sj.onc.1202175 9779989
41. Ashar HR James L Gray K Carr D Black S Armstrong L Bishop WR Kirschmeier P Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules J Biol Chem 2000, 275(39):30451-30457 10.1074/jbc.M003469200 10852915
42. Tamanoi F Gau CL Jiang C Edamatsu H Kato-Stankiewicz J Protein farnesylation in mammalian cells: Effects of farnesyltransferase inhibitors on cancer cells Cell Mol Life Sci 2001, 58(11):1636-1649 10.1007/PL00000802 11706990
43. Marks RE Ho AW Robbel C Kuna T Berk S Gajewski TF Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level Blood 2007, 110(6):1982-1988 10.1182/blood-2006-06-031088 17545504
44. St Clair EW Turka LA Saxon A Matthews JB Sayegh MH Eisenbarth GS Bluestone J New reagents on the horizon for immune tolerance Annu Rev Med 2007, 58:329-346 10.1146/annurev.med.58.061705.145449 16987079
45. Kohl NE Wilson FR Thomas TJ Bock RL Mosser SD Oliff A Gibbs JB Inhibition of Ras function in vitro and in vivo using inhibitors of farnesyl-protein transferase Methods Enzymol 1995, 255:378-386 8524123
46. Neri A Knowles DM Greco A McCormick F Dalla-Favera R Analysis of RAS oncogene mutations in human lymphoid malignancies Proc Natl Acad Sci U S A 1988, 85(23):9268-9272 282720 3057505 10.1073/pnas.85.23.9268
47. Sthoeger ZM Wakai M Tse DB Vinciguerra VP Allen SL Budman DR Lichtman SM Schulman P Weiselberg LR Chiorazzi N Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia J Exp Med 1989, 169(1):255-268 2189197 2462608 10.1084/ jem.169.1.255
48. Fais F Ghiotto F Hashimoto S Sellars B Valetto A Allen SL Schulman P Vinciguerra VP Rai K Rassenti LZ Kipps TJ Dighiero G Schroeder HW Jr. Ferrarini M Chiorazzi N Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors J Clin Invest 1998, 102(8):1515-1525 509001 9788964 10.1172/JCI3009
49. Dighiero G Hart S Lim A Borche L Levy R Miller RA Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas Blood 1991, 78(3):581-585 1859876
50. van de Donk NW Schotte D Kamphuis MM van Marion AM van Kessel B Bloem AC Lokhorst HM Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells Clin Cancer Res 2003, 9(15):5735-5748 14654559
51. McMaster ML Greer JP Greco FA Johnson DH Wolff SN Hainsworth JD Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy J Clin Oncol 1991, 9(6):941-946 1709685
52. Attias D Weitzman S The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: A review of available evidence Curr Opin Pediatr 2008, 20(1):17-22 10.1097/MOP.0b013e3282f424b0 18197034
53. Adams JM Harris AW Pinkert CA Corcoran LM Alexander WS Cory S Palmiter RD Brinster RL The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice Nature 1985, 318(6046);533-538 10.1038/318533a0 3906410
54. Hartley SB Crosbie J Brink R Kantor AB Basten A Goodnow CC Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens Nature 1991, 353(6346):765-769 10.1038/353765a0 1944535